07:22 AM EDT, 03/14/2025 (MT Newswires) -- ANI Pharmaceuticals ( ANIP ) said Friday that the US Food and Drug Administration has now approved Iluvien to treat chronic non-infectious uveitis affecting the eye's posterior segment.

The company intends to market the implant for chronic NIU-PS in addition to its current indication of diabetic macular edema in the US.

ANI shares were up 1.1% in recent premarket activity.